157 related articles for article (PubMed ID: 24907006)
61. Robotic stereotactic treatment for malignant metastasis of solid tumour in the pancreas: A multiple case report and review of literature.
Loi M; Magallon-Baro A; Papalazarou C; Milder M; Nuyttens JJ
Cancer Radiother; 2017 Dec; 21(8):784-787. PubMed ID: 29132801
[TBL] [Abstract][Full Text] [Related]
62. A Practical Workflow for Magnetic Resonance-Guided Stereotactic Body Radiation Therapy to the Pancreas.
Sim AJ; Hoffe SE; Latifi K; Palm RF; Feygelman V; Leuthold S; Dookhoo M; Dennett M; Rosenberg SA; Frakes JM
Pract Radiat Oncol; 2023; 13(1):e45-e53. PubMed ID: 35901947
[TBL] [Abstract][Full Text] [Related]
63. New territory: surgical salvage for stereotactic body radiation therapy failures in lung cancer.
Bradley J
J Thorac Oncol; 2010 Dec; 5(12):1879-80. PubMed ID: 21102255
[No Abstract] [Full Text] [Related]
64. [Normal tissue tolerance to external beam radiation therapy: Bone marrow and cortical bone structures].
Schernberg A; Hennequin C
Cancer Radiother; 2017 Oct; 21(6-7):619-625. PubMed ID: 28774489
[TBL] [Abstract][Full Text] [Related]
65. Pulmonary atelectasis after stereotactic ablative radiotherapy for a central lung tumor.
Senthi S; Ullmann EF; Senan S
J Thorac Oncol; 2013 Nov; 8(11):e94-5. PubMed ID: 24128724
[No Abstract] [Full Text] [Related]
66. Immunomodulatory effect of stereotactic ablative radiotherapy in lung cancer.
Domagała-Kulawik J
Pol Arch Intern Med; 2017 Apr; 127(4):233-234. PubMed ID: 28452968
[No Abstract] [Full Text] [Related]
67. A new era of thoracic oncology? Ex-vivo stereotactic ablative radiosurgery within Ex-vivo Lung Treatment System as a hybrid therapy for unresectable locally advanced pulmonary malignancies.
Henkenberens C; Zinne N; Biancosino C; Höffler K; Schmitto JD; Bremer M; Haverich A; Krüger M
Med Hypotheses; 2016 Jul; 92():31-4. PubMed ID: 27241251
[TBL] [Abstract][Full Text] [Related]
68. Creating a Sustainable Future of Radiotherapy Following COP26: A Case for Lung Stereotactic Ablative Radiotherapy Over Surgery?
Stanford-Edwards C; Edwards M; Selby A; Lewis R; Powell C; Nicholas O
Clin Oncol (R Coll Radiol); 2022 Mar; 34(3):e105-e106. PubMed ID: 34895991
[No Abstract] [Full Text] [Related]
69. It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible.
Brunelli A
J Thorac Cardiovasc Surg; 2018 Sep; 156(3):1247-1248. PubMed ID: 29754789
[No Abstract] [Full Text] [Related]
70. [Technical aspects and indications of extracranial stereotactic radiotherapy].
Bazire L; Darmon I; Calugaru V; Costa É; Dumas JL; Kirova YM
Cancer Radiother; 2018 Sep; 22(5):447-458. PubMed ID: 30064828
[TBL] [Abstract][Full Text] [Related]
71. [Elderly patients and radiotherapy: A short review].
Vallard A; Guy JB; Espenel S; Langrand-Escure J; Trone JC; Méry B; Moriceau G; Rivoirard R; de Laroche G; Chargari C; Magné N
Bull Cancer; 2015 Jun; 102(6):539-49. PubMed ID: 25840657
[TBL] [Abstract][Full Text] [Related]
72. Vocal cord paralysis after stereotactic body radiation therapy to the left lung apex.
Carpenter TJ; Rosenzweig KE
J Thorac Oncol; 2014 Nov; 9(11):e80-1. PubMed ID: 25436809
[No Abstract] [Full Text] [Related]
73. [Practice changing clinical trials in radiation oncology in 2022].
Antoni D; Claude L; Laprie A; Lévy A; Peignaux K; Rivera S; Schick U
Cancer Radiother; 2022 Oct; 26(6-7):823-833. PubMed ID: 36055908
[TBL] [Abstract][Full Text] [Related]
74. Treatment strategies for malignant pulmonary nodule: beyond lobectomy. Point-counterpoint.
Chang ATC; Ng CSH; Nezami N
Curr Opin Pulm Med; 2024 Jan; 30(1):35-47. PubMed ID: 37916619
[TBL] [Abstract][Full Text] [Related]
75. The course of lung oligometastatic colorectal cancer may be a reflection of selection for treatment rather than an effect of stereotactic body radiotherapy.
Macbeth F; Treasure T
Strahlenther Onkol; 2021 Jan; 197(1):74-75. PubMed ID: 33242138
[No Abstract] [Full Text] [Related]
76. Reply to: The course of lung oligometastatic colorectal cancer may be a reflection of selection for treatment rather than an effect of stereotactic body radiotherapy.
Nicosia L; Cuccia F; Alongi F
Strahlenther Onkol; 2021 Jan; 197(1):76-78. PubMed ID: 33242139
[No Abstract] [Full Text] [Related]
77. Dose Tolerance for Stereotactic Body Radiation Therapy.
Grimm J
Semin Radiat Oncol; 2016 Apr; 26(2):87-8. PubMed ID: 27000503
[No Abstract] [Full Text] [Related]
78. Should We be Offering Our Patients With Oligometastases Stereotactic Ablative Body Radiotherapy?
Ostler P; Hoskin P; Martin A
Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):747-748. PubMed ID: 34642067
[No Abstract] [Full Text] [Related]
79. Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy - No.
Macbeth F; Hughes-Davies L
Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):749-750. PubMed ID: 34218999
[No Abstract] [Full Text] [Related]
80. Should stereotactic ablative body radiotherapy be the standard of care in oligometastatic cancer?
Correa RJM; Palma DA
Lancet Oncol; 2021 Jan; 22(1):6-8. PubMed ID: 33387496
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
